Working... Menu
Trial record 42 of 453 for:    applied AND ointment

MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00513994
Recruitment Status : Completed
First Posted : August 9, 2007
Last Update Posted : April 11, 2008
Information provided by:
MediQuest Therapeutics

Brief Summary:
The purpose of the study is to measure how much nitroglycerin or its metabolites may be found in the bloodstream when MQX-503 or an FDA approved Nitroglycerin ointment 2% USP is applied to the skin of healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Nitroglycerin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: MQX-503 Applied to the Fingers vs. Nitroglycerin Ointment 2%, USP, Applied to the Chest: A Pharmacokinetic Comparison in Normal Subjects
Study Start Date : August 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1 Drug: Nitroglycerin
MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
Other Name: MQX-503, Nitro-Bid

Primary Outcome Measures :
  1. The primary objective is the measurement and comparison of the levels of nitroglycerin and its metabolites in the blood of healthy human volunteers after a single topical dose of MQX-503 and a single topical dose of Nitroglycerin Ointment 2%, USP. [ Time Frame: 8 hours ]

Secondary Outcome Measures :
  1. A secondary objective is the observation of the volunteers for any adverse events [ Time Frame: 2 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers 18 - 70 years of age.
  • Subjects able to give written informed consent and comply with study requirements.
  • Subjects willing and able to safely discontinue all current prescription therapies.
  • Subjects who will agree not to participate in other clinical trials.
  • Negative pregnancy test in fertile females and agreement to use effective contraception throughout the study.

Exclusion Criteria:

  • Persons who would be put at risk by discontinuing prescription therapies.
  • Subjects with a known allergy to nitroglycerin.
  • Subjects who have a condition or issue that would adversely affect the application of study medication, study evaluations or the subject's ability to comply with the protocol.
  • Subjects who recently experienced myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension or uncontrolled hypertension.
  • Subjects who have participated in a study of an investigational drug within two weeks of visit 1.
  • Subjects who have screening lab values that are out of range or are considered clinically significant by the investigator.
  • Subjects who have had major abdominal, thoracic, or vascular surgery within 6 months of visit 1.
  • Subjects with non-epithelialized skin lesions or interfering skin conditions at the time of screening in the area where study medication is to be applied.
  • Pregnant or nursing women.
  • Women of childbearing potential who are unwilling to comply with the contraceptive requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00513994

Layout table for location information
United States, Washington
Charles River Clinical Services
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
MediQuest Therapeutics
Layout table for investigator information
Principal Investigator: Adel Nada, M.D. Charles River Clinical Research

Layout table for additonal information Identifier: NCT00513994     History of Changes
Other Study ID Numbers: 07-002
First Posted: August 9, 2007    Key Record Dates
Last Update Posted: April 11, 2008
Last Verified: April 2008

Keywords provided by MediQuest Therapeutics:
pharmacokinetics study of nitroglycerin containing treatments

Additional relevant MeSH terms:
Layout table for MeSH terms
Vasodilator Agents